The firm saw an improvement in progression-free survival for patients on the ivonescimab regimen and a trend toward improved overall survival.

The approval was based on results from a Phase IIb trial demonstrating a 15.5-month median overall survival on Ziihera.

A patient participating in the Phase III MAGNITUDE trial of nex-z experienced asymptomatic grade 4 liver transaminase elevations, the firm reported.

Due to financial, logistical, and regulatory barriers, only two in 10 patients eligible for CAR T-cell therapy in the US ...

The firm submitted data showing that more than 70 percent of patients with HER2-mutated NSCLC who hadn't received anti-HER2 therapy responded to sevabertinib.

The approval was based on results from the Phase II HORIZON-Lung trial, in which the treatment had a median progression-free survival of 11.5 months.

Drugmakers are turning to biomarkers, like folate receptor alpha, and even cell therapies to tackle this deadly cancer in new ...

The firm will study AKY-1189 in Nectin-4-expressing tumors, including urothelial and triple-negative breast cancer.

The biotech startup, a spinout of the University of Colorado Anschutz Medical Campus, launched this year with $15 million in ...

Taysha expects to initiate the pivotal study, which will be part B of an ongoing Phase I/II trial, of TSHA-102 in the third quarter.

Regulators will review data on satri-cel's ability to treat advanced Claudin18.2-positive tumors in an expedited timeline.

The firm will use the proceeds from the private placement to advance its clinical-stage cardiomyopathy gene therapy programs.